| *Meeting report: Global vaccine and immunization research forum | Andrew Ford, Angela Hwang, B. Fenton Hall, Joachim Hombach, Nancy Touchette | 2018 | Journal article | Anglais |
| Context and Purpose of GVIRF | Thomas Cherian | 2016 | Report | Anglais |
| KN1 Opening Session and Dr Margaret Chan Keynote | GVIRF Secretariat | 2016 | Report | Anglais |
| KN3 Vaccine Manufacturing in Africa: Self-sufficiency, a need? Or a dream? | William Ampofo | 2016 | Presentation | Anglais |
| P1.1a RSA & HIV vaccine efficacy studies | Glenda Gray | 2016 | Presentation | Anglais |
| P1.1b HIV Vaccines: Marry HIV efficacy studies to science, but take shots on goal | Nelson Michael | 2016 | Presentation | Anglais |
| P1.2a TB Vaccine Research and Development: Progress, Strategies and Controversies | Lewis Schrager | 2016 | Presentation | Anglais |
| P1.3a Malaria Vaccines | Eusebio Macete | 2016 | Presentation | Anglais |
| P1.3b Vaccines for Malaria - Updates on Progress | Mahamadou Thera | 2016 | Presentation | Anglais |
| P2 The role of moderate efficacy vaccines in integrated disease control strategies | Katherine L. O'Brien | 2016 | Report | Anglais |
| P2.1 The role of moderate efficacy vaccines in integrated disease control strategies: Introduction | Kathleen Neuzil | 2016 | Presentation | Anglais |
| P2.2 Lessons from Rotavirus and Pneumococcal Conjugate Vaccines | Katherine L. O'Brien | 2016 | Presentation | Anglais |
| P2.3 Moderate efficacy malaria vaccines as part of comprehensive malaria control and elimination | Salim Abdullah | 2016 | Presentation | Anglais |
| P2.4 Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures | Walter Jaoko | 2016 | Presentation | Anglais |
| P3 Evolving Global Vaccine Markets | A. Batson | | Report | Anglais |
| P3.1 Global vaccine market | Amie Batson | 2016 | Presentation | Anglais |
| P4 Preparing for the next Infectious Disease Emergency | Helen Rees, Norman Baylor | | Report | Anglais |
| P4.1 Preparing for the inevitable | David Wook | 2016 | Presentation | Anglais |
| P4.2 Preparing for the Next Infectious Disease Emergency | Lucille Blumberg | 2016 | Presentation | Anglais |
| P4.3 Regulatory Preparedness for the Next Infectious Disease Emergency | Delese Mimi Darko | 2016 | Presentation | Anglais |
| P5 New Technologies to Support Measles Elimination | A. A. Adeyemo | 2016 | Report | Anglais |
| P5.1 What are the measles vaccination coverage gaps? | Peter Strebel | 2016 | Presentation | Anglais |
| P5.2 The Investment Case for Measles Eradication | Kimberly Thompson | 2016 | Presentation | Anglais |
| P5.3 Measles and Rubella Research Agenda | Narendra K Arora | 2016 | Presentation | Anglais |
| P5.4 An emerging vaccine delivery technology for measles and rubella elimination | James Goodson | 2016 | Presentation | Anglais |
| P6.1 Universal Influenza Vaccine Development | Barney S. Graham | 2016 | Presentation | Anglais |
| P6.2 Vaccine development for Group A Streptococcus | Andrew Steer | 2016 | Presentation | Anglais |
| P6.3 Schistosomiasis Vaccine Updates | Annie Mo | 2016 | Presentation | Anglais |
| P6.4 Preferred Product Characteristics | David Kaslow | 2016 | Presentation | Anglais |
| W1.0 Introduction: Applying Novel Technologies to Vaccine Development | Rino Rappuoli | 2016 | Presentation | Anglais |
| W1.1 Structural studies of viral envelope proteins and insights for vaccine design | Felix Rey | 2016 | Presentation | Anglais |
| W1.2 Epitope-focused vaccine design | Bill Schief | 2016 | Presentation | Anglais |
| W1.3 Design of self-assembling protein nanomaterials as next.generation vaccine scaffolds | Neil King | 2016 | Presentation | Anglais |
| W10.1 Monoclonal antibodies for infectious diseases | Martin Friede | 2016 | Presentation | Anglais |
| W10.2 Passive vaccination as a global strategy for preventing RSV disease in infants | Filip Dubovsky | 2016 | Presentation | Anglais |
| W10.3 Gene-based Delivery of Broadly Neutralizing Antibodies for HIV Prevention | Wayne Koff | 2016 | Presentation | Anglais |
| W10.4 Rabies antibodies for Passive Post-exposure prophylaxis | Tsepo Tsekoa | 2016 | Presentation | Anglais |
| W11 Vaccine Hesitancy | Narendra Arora | 2016 | Report | Anglais |
| W11.1 Vaccine Hesitancy: what it means and what we need to know in order to tackle it | Robb Butler | 2016 | Presentation | Anglais |
| W11.2 Vaccine Hesitancy: Determining the scale of the challenge | Susan Goldstein | 2016 | Presentation | Anglais |
| W11.3 Tailoring Immunization Programmes (TIP): An example of tailoring communication on vaccinations targeting hard.to.serve communities in Sweden | Ann Lindstrand | 2016 | Presentation | Anglais |
| W11.4 Applying TIP to low and middle income settings: a case study from South Africa | Nicola Christofides and Janine Simon-Meyer | 2016 | Presentation | Anglais |
| W2 Comprehensive assessment of risks and benefits of vaccines: the example of Dengue | Lucky Slamet, Stephen Thomas | | Report | Anglais |
| W2.2 Public Health Criteria for Dengue Vaccine Risk/Benefit Assessment and Risk Management | Peter Smith | 2016 | Presentation | Anglais |
| W3 Total Systems Effectiveness | Carsten Mantel, Darin Zehrung, James Goodson, Jean-Pierre Amorij, Melissa Malhame, Mercy Mvundura, Messeret Shibeshi, Tina Lorenson | 2016 | Report | Anglais |
| W3.1 Introduction: Total Systems Effectiveness | Tina Lorenson | 2016 | Presentation | Anglais |
| W3.2 Total System Effectiveness | Tina Lorenson | 2016 | Presentation | Anglais |
| W3.3 Microarray patch case study: Measles-rubella vaccine | Darin Zehrung | 2016 | Presentation | Anglais |
| W3.4 Vaccine technology costs and health impact assessment tool | Mercy Mvundura | 2016 | Presentation | Anglais |
| W4.1 Introduction: Antimicrobial Resistance & Vaccines | A. A. Adeyemo | 2016 | Presentation | Anglais |
